Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer Clinical Trial

— AFUGEM  

Official title:

Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01964534
• Other study ID #: AFUGEM D12-2
• Secondary ID: 2013-001463-23
• Status: Active, not recruiting
• Phase: Phase 2
• First received: October 15, 2013
• Last updated: January 30, 2017
• Start date: December 12, 2013
• Est. completion date: July 2017

Study information

• Verified date: January 2017
• Source: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the combination of ABI-007 with gemcitabine or with LV5FU2.

Description:

Gemcitabine alone or the triplet combination of 5FU, irinotecan and oxaliplatin (FOLFIRINOX)are the reference 1st line treatment for metastatic pancreatic cancer.

The aim of the AFUGEM study is to evaluate the efficacy of weekly ABI-007 in combination with weekly gemcitabine or with fortnightly simplified LV5FU2 regimen in terms of progression-free survival in patients with previously untreated metastatic pancreatic cancer.

ABI-007 has been approved for commercialization in 38 countries, including the US, Canada, the EU, Australia, China, India and Korea for the treatment of women with metastatic breast cancer. ABI-007 alone and in combination is being evaluated in a number of cancers, including metastatic melanoma, non-small cell lung cancer, pancreatic cancer, and other solid tumors. Conditions which are responsive to paclitaxel such as non-hematological solid tumor malignancies are good clinical candidates for treatment with ABI-007.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 114
• Est. completion date: July 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed and dated informed consent, and willing and able to comply with protocol requirements,

2. Histologically or cytologically proven adenocarcinoma of the pancreas,

3. Metastatic disease confirmed (stage IV),

4. No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >12 months),

5. At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1 guidelines,

6. Age =18 years,

7. ECOG Performance status (PS) 0-2,

8. Hematological status: neutrophils (ANC) >1.5x109/L; platelets >100x109/L; haemoglobin =9g/dL,

9. Adequate renal function: serum creatinine level <150µM,

10. Adequate liver function: AST (SGOT) and ALT (SGPT) =2.5xULN (=5xULN in case of liver metastases)

11. Total bilirubin =1.5 x ULN, albumin =25g/L

12. Baseline evaluations performed before randomization: clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to randomization,

13. Female patients must be surgically sterile, or be postmenopausal, or must commit to using reliable and appropriate methods of contraception during the study and during at least six months after the end of study treatment (when applicable). All female patients with reproductive potential must have a negative pregnancy test (ß HCG) within 72 hours prior to starting ABI-007 treatment. Breastfeeding is not allowed. Male patients must agree to use effective contraception in addition to having their partner use a contraceptive method as well during the trial and during at least six months after the end of the study treatment,

14. Registration in a national health care system (CMU included for France).

Exclusion Criteria:

1. History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy)

2. Local or locally advanced disease (stage I to III),

3. Patient uses warfarin,

4. Uncontrolled hypercalcemia,

5. Pre-existing permanent neuropathy (NCI grade =2),

6. Known dihydropyrimidine dehydrogenase (DPD) deficiency,

7. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),

8. Treatment with any other investigational medicinal product within 28 days prior to study entry,

9. Other serious and uncontrolled non-malignant disease (eg. active infection requiring systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6 months),

10. Known or historical active infection with HIV, or known active infection untreated with hepatitis B or hepatitis C.

11. History or active interstitial lung disease (ILD),

12. Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,

13. Patients with known allergy to any excipient of study drugs,

14. Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine and concomitant administration of prophylactic phenytoin

Related Conditions & MeSH terms

• Metastatic Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• ABI-007
ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
• Gemcitabine
1000 mg/m² IV /30min (day 1, day 8, day 15)
• simplified LV5FU2
Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)

Locations

Country	Name	City	State
France	Institut de cancérologie de l'Ouest - Paul Papin	Angers
France	Institut Sainte Catherine	Avignon
France	Hôpital Avicenne	Bobigny
France	Hôpital Beaujon	Clichy
France	Hôpital Henri Mondor	Créteil
France	Hôpital Privé Jean Mermoz	Lyon
France	CHU la Timone	Marseille
France	Centre Hospitalier Layné	Mont de Marsan
France	Hôpital Européen Georges Pompidou	Paris
France	Hôpital Pitié-Salpêtrière	Paris
France	Hôpital Saint Antoine	Paris
France	Institut Mutualiste Montsouris	Paris
France	CHU de Reims Hôpital Robert Debré	Reims
France	Institut de Cancérologie de l'Ouest - Réné Gauducheau	Saint Herblain
France	Hôpital Trousseau - CHRU Tours	Tours

Sponsors (2)

Lead Sponsor	Collaborator
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)	Celgene Corporation

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	To evaluate the efficacy of weekly ABI-007 in combination with weekly gemcitabine or with fortnightly simplified LV5FU2 regimen in terms of progression-free survival in patients with previously untreated metastatic pancreatic cancer	time interval from randomization to the date of first documented disease progression or death from any cause, whichever occurs first.Assessed at 4 months.
Secondary	Tumor Response Rate	Assessed using RECIST version 1.1	Assessed every 2 months during treatment period (- Estimated treatment duration per patient : 6 months).
Secondary	Duration of disease control (DDC)		Assessed up to 30 months after the beginning of the study
Secondary	Overall Survival		time interval from inclusion to the date of death from any cause. Assessed up to 30 months after the beginning of the study.
Secondary	Quality of life	EORTC QLQ C-30	Assessed from study entry to 1 month after last study drug administration and up to 30 months after the beginning of the study.
Secondary	Number of Adverse Events	To evaluate the safety profile of ABI-007 in combination with sLV5FU2 (NCI CTCAE v4.0)	Assessed from study entry to 1 month after last study drug administration, assessed up to 30 months after the beginning of the study